Table 3. FDG-PET and CT imaging responses (n=12).
| Patient No. | Site of disease assessed | Pretreatment SUV1 | 4 weeks post-treatment SUV2 | % reduction (1-SUV2/SUV1) | Qualitative visual response | CT response | Status |
|---|---|---|---|---|---|---|---|
| 1 | Primary | 11.39 | 6.9 | 39.4 | PMR | SD | DoD |
| Liver | 5.67 | 6.55 | UN | PD | 4mo | ||
| 2 | Primary | 6.43 | 2.99 | 53.5 | PMR | SD | DoD |
| Liver | 7.92 | 5.33 | 32.7 | PMR | SD | 9mo | |
| 3 | Primary | 12 | 3.1 | 74.2 | PMR | SD | DoD |
| Liver | 10.2 | 8.1 | 20.5 | UN | SD | 24mo | |
| 4 | Primary | 9.6 | 3.6 | 62.5 | PMR | SD | DoD |
| Para-aortic node | 7.9 | 4.8 | 39.2 | UN | PR | 12mo | |
| 5 | Primary | 5.2 | 1.4 | 73.1 | CMR | CR | AWD |
| Liver | 4.7 | 4.4 | 6.3 | PMR | SD | ||
| 6 | Primary | 14.1 | 7.35 | 47.9 | PMR | SD | NED |
| 7 | Primary | 10 | 4.5 | 55 | CMR | N/E | AWD |
| Liver | 5.2 | 4.3 | 17.3 | PMR | CR | ||
| 8 | Primary | 13.6 | 5.41 | 60.2 | CMR | SD | AWD |
| Liver | NU | NU | SD | ||||
| 9 | Primary | 7.33 | NU | 100 | CMR | SD | AWD |
| Bone | 4.76 | 2.61 | 45.1 | PMR | SD | ||
| 10 | Primary | 6.8 | 1.5 | 77.9 | CMR | N/Ea | DoD |
| Liver | 8.7 | 6.2 | 28.7 | UN | SD | 11mo | |
| 11 | Primary | 13.8 | 5.9 | 57.2 | PMR | PD | AWD |
| Liver | 8.4 | 7.8 | 7 | UN | SD | ||
| 12 | Primary | 7.3 | 4.9 | 32.8 | UN | SD | DoD |
| Liver | 6.7 | 5.1 | 23.8 | UN | SD | 14 mo | |
| Lung | 2.6 | 2.4 | 7.7 | UN | SD | ||
FDG-PET=Fluorine-18 fluoro-deoxyglucose positron emission tomography; CT=computed tomography; SUV: standardised uptake value; ND: not done; NU: no uptake; CMR: complete metabolic response; PMR: partial/incomplete metabolic response; PD: progression; N/E: not evaluable. UN: unchanged metabolic response; AWD: alive with disease; DOD: dead of disease; NED: no evidence of disease; mo: months.
a
CR observed on clinical examination.